11 research outputs found
Data of relapsed patients both at diagnosis and at relapse.
<p>HP: erradication therapy; F: Fludarabine; Chemo: Chemotherapy.</p>*<p>Time to relapse in months.</p
Clinical characteristics of gastric MALT lymphoma patients at study entry.
<p>Clinical characteristics of gastric MALT lymphoma patients at study entry.</p
Kinetics of CD3+, FOXP3+, ratio FOXP3+/CD3+ and CD20+ cells by immunohistochemistry in responding patients.
<p>Median CD20+ cells were significantly different between cases treated with antibioticis and those treated with fludarabine or bendamustine with or without Rituximab at first response evaluation (p = 0.001) but not later during follow-up.</p
Immunohistochemistry by gastric condition (cells/mm<sup>2</sup>).
<p>MALT: mucosa-associated lymphoid tissue; DLBCL: diffuse large B-cell lymphoma; CG: chronic gastritis; HP: <i>Helicobacter pylori</i>.</p
Immunohistochemistry for CD20 and FOXP3 at study entry and at first response evaluation (1–2 months after finishing treatment).
<p>Gastric biopsies samples from 4 gastric MALT lymphoma patients treated with different schedules. HP: erradication therapy alone; RQ: Rituximab+CHOP; RF: Rituximab+Fludarabine; RB: Rituximab+Bendamustine.</p
Diferential impact of RDI reduction in R-CHOP21 and R-CHOP14 cohorts.
<p>Diferential impact of RDI reduction in R-CHOP21 and R-CHOP14 cohorts.</p
Main clinical characteristics of the patients.
<p>Main clinical characteristics of the patients.</p
Prognostic factors influencing OS and PFS in the global group.
<p>Prognostic factors influencing OS and PFS in the global group.</p